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Abstract
Objectives—Recent advances in the design of MRI contrast agents have rendered the lanthanide
complexes of DOTA-tetraamide ligands of considerable interest, both as responsive MR agents and
paramagnetic chemical exchange saturation transfer agents. The potential utility of these complexes
for in vivo applications is contingent upon them being well tolerated by the body. The purpose of
this study was to examine how the nature of the amide substituent, and in particular its charge, affected
the fate of these chelates postinjection.
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Materials and Methods—Complexes of 6 DOTA-tetraamide ligands were prepared in which the
nature of the amide substituent was systematically altered. The 6 ligands formed 3 series: a
phosphonate series that included tri-cationic, mono-anionic, and polyanionic complexes; a
carboxylate series made up of a tri-cationic complex and a mono-anionic complex; and lastly, a tricationic complex with an aromatic amide substituent. These complexes were labeled with an
appropriate radioisotope, either 153Gd or 177Lu, and the biodistribution profiles in rats recorded 2
hours postinjection.
Results—Biodistribution profiles were initially acquired at low doses to minimize adverse effects.
All the complexes studied were found to be excreted primarily through the renal system, with the
majority of the dose being found in the urine. None of the complexes exhibited substantial uptake
by bone, liver, and spleen, except for a complex with 4 phosphonate groups that exhibited significant
bone targeting capabilities. Increasing the dose of each complex to that of a typical MR contrast agent
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was found to render all 3 tri-cationic complexes studied here acutely toxic. In contrast, no ill effects
were observed after administration of similar doses of the corresponding anionic complexes.
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Conclusions—The absence of uptake by the liver and spleen indicate that irrespective of the ligand
structure and charge, these complexes are not prone to dissociation in vivo. This is in agreement with
previously published work that indicates high kinetic inertness for this class of compounds. At low
doses, all complexes were well tolerated; however, for applications that require higher doses, the
structure and charge of the ligand becomes a fundamentally important parameter. The results reported
herein demonstrate the importance of incorporating negatively charged groups on amide substituents
if a DOTA-tetraamide complex is to be employed at high doses in vivo.
Keywords
Lanthanide complexes; Biodistribution; MRI contrast agents; PARACEST agents
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Complexes of Gd3+have found widespread application as contrast agents in magnetic
resonance imaging (MRI)1,2 in which they are administered in relatively high doses, typically
0.1– 0.5 mmol kg−1. Numerous Gd3+ complexes have been approved for clinical use and,
without exception, the ligand systems employed are octadentate polyamino-polycarboxylates
that render the resulting complex either neutral or negatively charged.1,2 These complexes
have high thermodynamic stability constants and are considered inert to dissociation under
physiological conditions3; they are therefore excreted intact, usually through the renal system,
3,4 within several hours of injection. All clinically approved agents also have in common a
single coordinated water molecule. This water molecule, which is in relatively rapid exchange
with the bulk solvent, contributes significantly to the relaxivity of the contrast agent. Relaxivity,
the increase in water proton relaxation rate per unit concentration of contrast agent, is the
measure of the effectiveness of the agent. One of the most successful contrast agents is the
Gd3+ complex of DOTA (H4DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid), a ligand based on the tetraazamacrocycle cyclen.
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The tetraamide derivatives of DOTA (generic structure shown in Fig. 1) form complexes with
lanthanide ions that are structurally analogous to those of DOTA.5 However, unless ionizable
groups, such as carboxylates or phosphonates, are incorporated into the ligand, the resulting
Ln3+ complexes will be tri-cationic in nature. It is now an accepted feature of these complexes
that the exchange kinetics of the coordinated water molecule is much slower than that in the
corresponding polyamino-polycarboxylate complexes.5–9 The slow water exchange kinetics
of these DOTA-tetraamide complexes was found to limit their relaxivities,5–9 and hence their
potential as MRI contrast agents. However, this perceived shortcoming has since been found
to be a favorable attribute. The Gd3+ complex of a DOTA-tetraamide ligand that has methylene
phosphonate amide substituents, Gd1 (see Appendix), was found to act as a pH-sensing contrast
agent.10 The mechanism of action of this agent involves the pH-dependent acceleration of
water proton exchange between the coordinated and bulk water by the pendant phosphonate
groups.10 This gives rise to low relaxivity when exchange is slow and higher relaxivity under
the faster change regimen. The pH range over which this complex exhibits its change in
relaxivity is ideal for measuring change in pH in vivo and pH maps of kidneys and tumors in
mice have been acquired using this agent.11–13
DOTA-tetraamide complexes have also shown the potential for generating contrast in MR
imaging through chemical exchange saturation transfer (CEST). These paramagnetic CEST
agents, often referred to as PARACEST agents,14,15 offer some potential advantages over
conventional Gd3+-based contrast agents. In the complexes of Ln3+ ions that induce large
hyperfine shifts, such as Eu3+, Tm3+, Dy3+ and Nd3+, the protons of the slowly exchanging
coordinated water molecule are shifted far away from the bulk water and hence can easily be
saturated by use of a frequency-selective presaturation pulse without directly saturating the
Invest Radiol. Author manuscript; available in PMC 2009 June 16.
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solvent water signal itself. Subsequent exchange of these protons with those of the bulk
transfers the saturation to the solvent water, thereby reducing its signal intensity and resulting
in negative image contrast.
The CEST properties of an agent are assessed by recording a CEST spectrum in which the
solvent water signal intensity, as a percentage of its initial intensity (MS/M0 %), is plotted
against the frequency offset of the presaturation pulse.14 Eu3+ is commonly employed as the
basis of PARACEST agents because it has been reported to have the slowest water exchange
kinetics of all Ln3+ ions in this type of complex.16 The CEST spectra of Eu2 show a peak at
~+50 ppm characteristic of CEST arising from the water molecule coordinated to Eu3+ (Fig.
2). The more intense peak at 0 ppm is the result of direct saturation of the solvent water protons.
The Ln3+ complexes of 4 and 5 have also been extensively studied and found to have favorable
CEST properties.9,17–23 In contrast, the exchange kinetics of the coordinated water molecule
protons in Ln1 complexes are too rapid for a CEST effect to be observed for Eu1. Fitting the
CEST spectra of Eu2 to the Bloch equations modified for exchange24 afforded a value of τM
= 67 ± 6 μs (τM = 1/kex) longer than that of Ln1 but shorter than those of Eu3 (τM = 1.3
milliseconds).25
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This new method of generating image contrast offers several advantages over conventional
agents, particularly in the development of targeted agents (in which motion artifacts can be
reduced by interleaving images acquired with and without saturation)26 and responsive agents
(in which ratio-metric detection can be used to eliminate the question of contrast agent
concentration).27 However, if this class of compounds is to be used for in vivo applications
then developing an understanding of how these compounds are tolerated by the body and their
fate postinjection is imperative. As a first step toward this understanding, we have undertaken
some in vivo investigations of a number of DOTA-tetraamide complexes (see Appendix) that
differ in overall charge (see structures in Fig. 1).

MATERIALS AND METHODS
General Remarks
All solvents and reagents were purchased from commercial sources and used as received unless
otherwise stated. The preparation of ligands 1,10 3,10 4,28 5,9 and 68 has been described
previously. 1H and 13C NMR spectra were recorded on a Bruker Avance III spectrometer
operating at 400.13 and 100.62 MHz, respectively. 1H NMR and CEST spectra were recorded
on a Varian Mercury spectrometer operating at 299.99 MHz.
Synthesis

NIH-PA Author Manuscript

1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetamidomethylene-(ethyl)
phosphonate Sodium Salt (2)—A 1 M solution of sodium hydroxide (0.4 mL) was added
to a solution of ligand 3 (0.1 g, 0.1 mmol) in water (6 mL). The resulting solution was heated,
with stirring, at 80°C for 18 hours. After cooling to room temperature, the solvents were
removed by freeze-drying to afford the title compound as a colorless solid in quantitative yield.
Mp, decomposes >244°C; 1H NMR (400 MHz, D2O) δ = 3.87 (4H, q, 3JH-H = 6 Hz, OCH2),
3.85 (4H, q, 3JH-H = 6 Hz, OCH2), 3.42 (8H, d, 2JP-H = 15 Hz, PCH2NH), 3.13 (8H, s br,
NCH2CO), 2.59 (8H, s br, ring NCH2), 2.38 (8H, s br, ring NCH2), 1.18 (12H, t, 3JH-H = 6
Hz, CH3); 13C NMR (100 MHz, D2O) δ = 16.1 (d, 3JP-C = 6 Hz, CH3), 35.6 (d, 1JP-C = 147
Hz, PCH2NH), 50.2 (s br, ring NCH2), 57.0 (s, NCH2CO), 61.3 (d, 2JP-C = 6 Hz, OCH2), 172.9
(d, 3JP-C = 6 Hz, C = O); 31P NMR (121 MHz, D2O) δ = 19.1 (s, CH2P(OEt)O2Na); m/z (ESI
-) = 887 (60%, [H3L]−), 909 (100%, [NaH2L]−), 925 (75%, [KH2L]−) 931 (90%, [Na2HL] −),
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947 (90%, [NaKHL]−), 953 (70%, [Na3L]−), 969 (45%, [Na2KL]−); Anal found C 26.8%, H
6.1%, N 8.7%; C28H56N8Na4O16P4 • KCl • 11H2O requires C 26.9%, H 6.3%, N 9.0%.
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Europium(III) 1,4,7,10-Tetraazacyclododecane-1,4,7,10tetraacetamidomethylene-(ethyl)phosphonate Sodium Salt (Eu2)—Ligand 2 (50
mg, 51 μmol) was dissolved in water (5 mL) and europium chloride (17 mg, 46 μmol) added.
The solution was heated, with stirring, to 60°C for 18 hours. The solvents were then lyophilized
to afford the title complex as a colorless solid in quantitative yield. The complex was used
without further purification.
NMR (300 MHz, D2O) δ = 24.88 (4H, s, ring axS), 3.16 (4H, s, CH2P), 0.83 (4H, s,
CH2P), −2.89 (4H, s, ring eqS), −5.02 (4H, s, ring axC), −8.56 (4H, s, ring eqC), −9.96 (4H, s,
ac), −12.86 (4H, s, ac).

1H

Radiochemistry
177Lu
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Method 1—177Lu, produced by neutron irradiation of isotopically enriched 176Lu
(NO3)3 and dissolved in 0.05N HCl, was purchased from the University Missouri Research
Reactor. All reaction vials were washed with 10%–20% nitric acid overnight. Ligands 2, 3,
and 5 were labeled with 177Lu by adding 1 μL of the 177LuCl3 solution (100 –200 μCi) to 100
μL of a 0.4 M ammonium acetate buffer (pH = 7.5) containing the ligand solution at 5 mM.
The reaction mixture was then incubated at 90°C for 1 hour in an Eppendorf thermo-mixer at
1,000 rpm. The radiochemical reactions were monitored by a Rita Star Radioisotope TLC
Analyzer (Straubenhardt, Germany).
177Lu Method 2—A stock isotope solution was prepared by adding 2 μL of a 0.3 mM solution
of 177LuCl3 in 0.1 M HCl to a 3 × 10−4 M LuCl3 carrier solution. Appropriate ligand solutions

were then prepared at approximately the same concentration in deionized water. Complexation
was conducted by combining a 5% excess of a ligand solution with the isotope (pH 2) and
gradually increasing the pH to 7 by addition of 0.1 M NaOH. Complexation was monitored
and the final complex purified by passing the solution (100 μL) through a Sephadex C-25
column eluting with 4:1 saline (0.85% NaCl/NH4OH; 2 × 3 mL). The amount of radioactivity
in the eluent (complex) versus the amount remaining on the column (free metal) provided an
index of complexation.
153Sm
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Method—153Sm2O3, with a specific activity >5 GBq/mg, was produced at the ITN
(Instituto Tecnológico e Nuclear), Lisbon. The 153Sm-oxide was prepared from a 98% enriched
target, sealed into a quartz vial and welded into an aluminum can, by neutron irradiation using
a thermal flux of 2.3 × 1013 n/cm2 s. Following irradiation, the sample was opened, dissolved
in 1N HCl and brought to a stock concentration of 1.9 × 10−3 M. Stock solutions of the ligand
6 (30 μg) were prepared in isotonic HEPES pH 6.8 buffer (2 mL), mixed with the radioactive
metal chloride (4 mCi), heated for 10 hours at 85°C, and kept overnight at room temperature.
The radiochemical purity of the 153Sm6 solutions was determined by thin layer
chromatography, and the percentage of bound metal averaged 96%.
153Gd Method—The concentration of ligand 1 was estimated by dissolving a known amount

in D2O and comparing proton integrals to those of a standard, potassium hydrogen phthalate.
Ligand 1 (151.2 mg) was dissolved in 2 mL of nanopure water and 241 μCi of 153GdCl3 (Perkin
Elmer Life Sciences, Billerica MA) was added. The pH was adjusted to 4 and the solution was
heated at 60°C overnight. Solid GdCl3 (60.31 mg, 229 μmol) was added to the solution, the
pH adjusted to 5.5 with 1N sodium hydroxide and the solution stirred at 60°C for a week.
Radio-high-performance liquid chromatography (HPLC) indicated 3 peaks: free 153Gd, labeled
Gd1, and a later eluting impurity. The solution was purified using a 500 mg C-18 SepPak that
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had been pre-equilibrated with ethanol and then water. The radio-labeled mixture was put on
the column and eluted first with water and then a 3:1 water: ethanol mixture to elute the Gd1.
Fractions were analyzed by HPLC and pure fractions combined. Solvent was removed under
vacuum and the solid was reconstituted in water for the biodistribution studies. Concentration
of cold Gd1 was estimated from the activity in the sample of known volume.
GdDTPA was labeled with 111In by an exchange reaction. A gadopentetate dimeglumine
(Magnevist, Berlex, Wayne NJ) was diluted to 20 mM and to a 0.5 mL aliquot of this solution
was added 111InCl3 (Perkin Elmer Life Sciences, Billerica MA) and the pH adjusted to 4. The
solution was stirred at 40°C for 1 hour and the pH adjusted to 7 with sodium hydroxide. The
radiochemical purity was assessed by TLC and was >99%.
Biodistribution Studies
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All animal studies were performed in compliance with guidelines set by the Institutional
Animal Care and Use Committee (IACUC) of the University of Texas Southwestern Medical
Center at Dallas and the IACUC at Epix Pharmaceuticals. The 177Lu-labeled chelates were
diluted with 10 mM PBS (pH 7.4). Normal male Sprague-Dawley rats (Harlan, IN) weighing
170 –220 g were injected with 5 μCi of the 177Lu-labeled ligand via the tail vein. The total
injected volume was 100 μL. The rats were anesthetized before being killed 2 hours
postinjection (n = 4). Organs of interest were removed, weighed, and counted. Standards were
prepared and counted along with the samples to calculate the percent injected dose per gram
(% ID/g) and percent injected dose per organ (% ID/organ). Total percentage uptake in the
bone was calculated by assuming that the femur represents 1/25 of the total skeletal mass with
a uniform distribution. Representative samples of muscle and blood were counted and the total
percentage uptake calculated by assuming a total mass of 43% and 6.5%, respectively.29
Conscious male Sprague-Dawley rats (Charles River, Wilmington MA), 325–350 g, were
injected with 7 μCi 153Gd1 (35 μmol kg−1 Gd1) and 10 μCi of 111InDTPA (68 μmol kg−1
GdDTPA) via the tail vein. The labeled compounds were mixed immediately before injection.
The total injection volume was 250 μL. Blood samples were taken from the carotid artery,
which had been cannulated with a silicone tube before the study. Blood (150 –200 μL) was
taken before, and 1, 3, 5, 10, 15, 30, 60, 90, and 120 minutes postinjection of the labeled
compounds. At 120 minutes, the animals (n = 3) were euthanized by pentobarbital overdose
and the organs of interest were removed, weighed, and counted. Aliquots of the injection
solution were also weighed and counted to calculate %ID/g and %ID/organ. Three more
animals were injected via the tail vein, but without blood collection. These rats were killed 7
days after injection, and their organs removed, weighed, and counted along with aliquots of
the injection solution.

NIH-PA Author Manuscript

Determination of Partition Coefficients
The partition coefficients (log P) of 177Lu2 and 177Lu3 were determined by adding 5 μL of a
5 mM solution of each complex to a biphasic solution containing 500 μL of octanol and 500
μL of water (obtained from presaturated octanol/water, n = 10). The resulting mixture was
shaken at room temperature for 1 hour and then allowed to settle. From each of the 10 samples,
100 μL aliquots of the water and octanol phases were removed. The partition coefficient was
calculated as a ratio of the counts in the octanol fraction to the counts in the water fraction. An
average log P value was obtained from the 10 samples.
γ-Imaging
A gamma camera-computer system (GE 400 Genie-Acq, General Electrics, Milwaukee) was
used for acquisition and preprocessing. Data processing and display were performed on a
personal computer using homemade software developed for the IDL 5.2 computer tool. A wellInvest Radiol. Author manuscript; available in PMC 2009 June 16.
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counter (DPC-Gamma C12; LA) with a Compaq DeskPro compatible computer was used for
activity counting in the biodistribution studies. Dynamic gamma images were obtained using
250 g Wistar rats. All animal studies were carried out in compliance with procedures approved
by the appropriate institutional review committees. Conscious rats were allowed free access
of food and water ad libitum. Wistar rats (groups of 4 animals) were injected in the tail vein
with ca. 500 μCi of the 153Sm6 chelate. The animals were positioned in ventral de-cubitus over
the detector. Image acquisition was started immediately before the injection, using 64 × 64
matrices, the total acquisition time was 30 minutes. Images were subsequently processed using
an IDL-based program (Interactive Data Language, Research Systems, Boulder, CO). To
analyze the transport of radiotracer over time, 4 regions of interest were drawn on the image
files, corresponding to the brain, thorax, liver, and left kidney and time-activity curves were
obtained.

RESULTS
Biodistribution Studies
153Gd1
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and the 177Lu complexes of ligands 2 to 6 were administered to rats via tail vein
injection. Having been previously administered to mice with no adverse effects11,12 a
relatively high dose of 153Gd1 was administered: ~35 μmol kg−1. All other complexes were
administered at lower doses (1.2–1.5 μmol kg−1) to minimize possible adverse effects. In all
cases, no adverse reactions to the administration of the complexes were observed. The urine
was collected and at 2 hours postinjection the rats were killed, the organs excised, and the
radioactivity of each organ and urine was assessed. In each case, >95% of the total injected
radioactive dose was recovered. The data obtained are presented as % ID/g in Table 1 and %
ID/organ in Table 2. Two hours postinjection, the majority (>90% of the injected dose) of each
complex was found in the animals’ urine (data not shown).
Biodistribution studies at a typical MRI dose of 0.1 mmol kg−1 using 177Lu5 and 177Lu6 were
attempted. In each case, the animals were found to expire within 1 minute of administration of
the tri-cationic complex. As a result biodistribution studies at this higher dose were not
completed. Significantly, animals administered with the same 0.1 mmol kg−1 dose of Gd1 or
Eu4 exhibited no adverse effects.
Pharmacokinetics of Gd1
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The blood clearance of Gd1 was simultaneously compared with that of a similar hydrophilic
extracellular tracer, such as GdDTPA, to provide an assessment of its blood clearance kinetics.
There is little overlap between the γ-emission range of 111In and 153Gd and so both these
isotopes can be measured simultaneously. 111In was substituted for 153Gd in the DTPA
complex and 153Gd1 and 111InDTPA were administered to rats simultaneously to minimize
interanimal variability. After administration of the 2 complexes, blood was sampled at 9 timepoints from 1 to 120 minutes postinjection. Both compounds exhibited bi-exponential blood
clearance (Fig. 3), and a 2 compartment model was used to fit the data; the relevant fitting
parameters are listed in Table 3. Despite interanimal variation, the ratio of clearance rates for
Gd1 versus InDTPA, within a given animal, were very similar. Significantly, the blood halflife of Gd1 was found to be 60% shorter than that of InDTPA, which may be related to its fast,
and possibly irreversible, uptake in the bone. The bone uptake of 153Gd1 is highlighted by the
2-hour biodistribution of coinjected 153Gd1 and 111InDTPA, which reveals substantially higher
levels of bone activity for 153Gd1.
γ-Imaging Studies
A convenient method for following the biodistribution of a complex immediately after injection
is γ-imaging. By administering the complex radiolabeled with 153Sm, a γ-emitter, images can
Invest Radiol. Author manuscript; available in PMC 2009 June 16.
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be obtained using a simple γ-camera. Although this technique affords only qualitative
information about the distribution of the complex, it has the advantage that images can be taken
at rapid time intervals postadministration and the animals need not be killed. Figure 4 shows
images of a rat administered with a 0.2 μmol kg−1 dose of 153Sm6 at 3 time-points postinjection.
In the first image, taken 1 minute postinjection, the greatest signal intensity arises from organs
in the thorax: heart and lungs. Weaker, but clearly distinguishable, signals are also observed
from the kidneys. Images taken at 5 and 9 minutes postinjection clearly show the complex
being removed from the blood-pool by the kidneys and excreted into the urine and bladder. A
composite of all the images taken over this time period (Fig. 4 bottom) provides a clear picture
of which organs are exposed to the complex in the minutes postinjection: the heart, kidneys,
bladder, and urethra can all be identified.
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Mean activity/pixel values were obtained for 30 minutes after the injection of 153Sm6 into a
different animal. Three regions of interest (ROIs) were identified: 1 that included parts of the
liver and spleen; one for the thorax, containing primarily the heart and lungs; and 1 covering
part of the kidney. For each ROI, the curves were normalized relative to the maximum activity
observed for any pixel and then smoothed. The curves (Fig. 5) show a rapid increase in activity
as the complex is administered (<1 min) followed by continued activity over the course of the
experiment. Owing to the nature of the acquisition technique absolute intensities cannot be
compared in these curves, with differences in the tissue depth giving rise to different activities
in each ROI. However, the persistence of activity in the thorax indicates that a substantial
amount of the complex is retained by the blood showing up in the heart and lungs, both of
which are well perfused. This observation is consistent with the known affinity of this complex
for serum albumins.8 The complex is observed to slowly eliminate through the kidneys; this
slow elimination is also probably a product of the strong retention of the complex by the blood.
Perfused Heart Studies
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The effect of a tri-cationic complex upon heart tissue was examined in an isolated perfused
heart model. Hearts from anesthetized rats were surgically removed and immediately attached
via the aorta to a Langendorf perfusion apparatus and perfused with 200 mL of a bicarbonate
Krebs-Henseleit (KH) buffer (pH 7.4). The developed pressure, an indicator of heart function,
was monitored as Eu5 was added to the perfusate. Aliquots of 80 μmol of Eu5 were added to
the perfusate at 10-minute intervals for 40 minutes. The dosing was then stepped up to 160
μmol per addition and a further 4 aliquots added at 10-minute intervals. After each addition,
an immediate drop in the developed pressure was observed. After the first addition of Eu5, the
developed pressure recovered to a value higher than the initial value, but each subsequent
addition of Eu5 resulted in a decrease in the developed pressure once the heart stabilized (Fig.
6). Twenty minutes after the last addition of Eu5, the perfusate was replaced with fresh KH
buffer free of Eu5 and the developed pressure and heart rate quickly recovered to near initial
values (final heart rate = 255 bpm c.f. initial heart rate = 250 bpm).

DISCUSSION
Ligands 1–6 afford an opportunity to study the effect of the overall charge a complex has on
its properties. The Ln3+ complexes of ligands 3, 5, and 6 complexes, all of which are neutral
ligand systems, are tri-cationic. The overall charge of the complex can be altered by
incorporating ionisable groups into the amide substituents. Incorporating anionic amide
substituents affords mono-anionic complexes. Carboxylic acids and phosphonate mono-esters
generally have low protonation constants30 and remain deprotonated (anionic) over the
physiologically relevant pH range (pH 4 – 8); in consequence complexes Ln2 and Ln4 are
mono-anionic. The situation is more complex in the case of Ln1 complexes. Each phosphonate
has two protonation constants: one low and one in the pH range 5– 8 region,31 which means
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that there is a distribution of protonation states over this pH range. However, from a previously
published speciation diagram of these protonation states, it can be determined that at
physiological pH, around 60% of the Ln1 complex is completely deprotonated, ie, pentaanionic, and 40% is mono-protonated and thus tetra-anionic.10 Of particular interest here was
the effect of this change in charge upon the in vivo tolerance and biodistribution of these
complexes. Clearly, if these complexes are to be used for MR imaging purposes, and at the
high doses that MR imaging implies, it is important that they are well tolerated in vivo. Gd1
has been used in vivo to successfully acquire pH maps of mice without apparent adverse side
effects.11–13 On the other hand, anecdotal evidence has suggested that some tri-cationic
lanthanide DOTA-tetraamide derivatives may be toxic to rodents, and perhaps mammals in
general.

NIH-PA Author Manuscript

Our own interest in these Ln3+ DOTA-tetraamide complexes is their potential application as
MRI contrast agents, although these complexes may also be potentially useful in the field of
nuclear medicine. As pH responsive agents,10,12,13 interest centers around Gd3+ but as
PARACEST agents,14 any other paramagnetic Ln3+ ion may be of interest. Fortunately, all
Ln3+ ions exhibit very similar coordination chemistry and with the DOTA-tetraamide ligands
studied here, they all adopt the same mono-capped square antiprismatic coordination geometry.
8 –10 This means that the choice of Ln3+ ion is somewhat arbitrary since differences in the in
vivo behavior resulting from changing the metal ion are likely to be smaller than the errors in
our measurements. Because of our interest in its pH responsive behavior, 153Gd was chosen
as a radiolabel for ligand 1. For all other ligands, 177Lu was chosen because of convenient
access to this isotope.
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It is extremely important that a complex proposed for in vivo application is resistant to
dissociation under physiological conditions. Both ligands and Ln3+ ions are toxic (DOTA:
LD50 = 0.18 mmol kg−1;32 GdCl3: LD50 = 0.35 mmol kg−1;33 i.v. in mice), so at high doses a
complex that rapidly releases its metal ion would be toxic. Although the thermodynamic
stability constants determined for a range of lanthanide DOTA-tetraamide complexes are as
much as 6 orders of magnitude lower than the corresponding DOTA complexes,28,34 critically
this type of complex exhibits dissociation kinetics that are as much as 3 or 4 orders of magnitude
slower than the corresponding complexes of DOTA.28,34 This means that if DOTA-tetraamide
complexes are eliminated from the body as quickly as those of DOTA, then it is reasonable to
expect that in vivo dissociation will not occur to any significant extent. From the point of view
of complex dissociation, this should render these complexes safe for use in vivo.
Biodistribution studies can provide a valuable insight into the fate of a complex in vivo. The
free Ln3+ ion is a surrogate for the Ca2+ ion and consequently accumulates in teeth and
bone4,35,36; it may also form colloids with serum proteins that are cleared through the
reticuloendothelial system (RES) and Kupffer cells giving rise to higher than normal levels of
activity in the liver and spleen.4,35,36 Radioactivity in these organs can be an indication of
complex dissociation in vivo.
Anionic LnDOTA-Tetraamide Complexes
All 3 anionic DOTA-tetraamide complexes studied here, Ln1, Ln2, and Ln4, were found to be
excreted rapidly and exclusively through the renal system. At the low doses required for nuclear
medicine applications (1–35 μmol kg−1), these anionic complexes were well tolerated by the
animals. At the relatively high doses required for conventional MRI contrast agents (≥0.1 mmol
kg−1), complexes Ln1 and Ln4 were also found to be well tolerated in vivo and no adverse
effects were noted. Ln2 was not studied at higher doses. The kinetic inertness of the LnDOTAtetraamide complexes28,34 seems to render these complexes stable enough for use in vivo,
and the biodistribution data is consistent with the complexes remaining intact in vivo. In all
cases, the levels of activity in the liver and spleen were low for each complex. The level of
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activity in bone, another key indicator of complex dissociation, was also low for Ln2 and
Ln4. Indeed, the low levels of residual activity in all organs observed for these 2 mono-anionic
complexes 2 hours postinjection is reminiscent of the biodistribution profiles observed for
clinically approved macrocyclic contrast agents.3,4,37 Both Ln2 and Ln4 exhibit favorable
CEST profiles, even if their water exchange kinetics are faster than optimal as predicted by
theory.14,24 Since PARACEST agents are currently not yet as sensitive as conventional MRI
contrast agents, it is not yet clear what an effective dose of these agents would be. However,
the results of these studies are encouraging suggesting that, despite their relatively low
thermodynamic stabilities,28,34 these mono-anionic DOTA-tetraamide complexes are well
tolerated in vivo and are potentially viable as contrast media.
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The level of activity in bone was higher in the case of Ln1 although this can be attributed to
the known affinity of phosphonate ligands for bone.38 – 42 This means it is likely that Ln1
itself binds to bone rather than dissociating to free Ln3+ before bone uptake. The absence of
elevated levels of activity in the liver and spleen for Ln1, hallmarks of a free Ln3+ ion, are
consistent with the complex remaining intact. Ln1 is cleared from the blood more rapidly than
complexes of DTPA. This is probably the result of rapid kidney uptake and excretion coupled
with rapid uptake in the bone. The biodistribution data expressed as percent injected dose/organ
(Table 2) clearly shows the marked preference of 153Gd1 for bone, confirming the targeting
effect of the phosphonate groups. When 153Gd1 was administered to another cohort of rats and
its biodistribution determined 7 days postinjection, the level of 153Gd1 in bone was almost
identical to the 2 hour values. No retention of this complex in any of the other organs was
observed 7 days postinjection. The clear bone targeting properties of Ln1 may render it useful
for nuclear medicine applications in which bone targeting is desirable. It is a less attractive
property in an MRI contrast agent; the higher doses involved and the persistence of the complex
in bone raises certain questions over the long-term safety of administering high doses of this
complex. Notably, the apparent bone targeting effect of the phosphonates can be masked by
inclusion of at least one ester function in each phosphonate group; neither 177Lu2
nor 177Lu3 exhibit the same preference for bone. This effect seems to be analogous to that
observed when a phosphonate is replaced by a methyl or benzyl phosphinate, which has also
been shown to eliminate bone targeting effects.43 So although the polyanionic Gd1 certainly
has attractive pH reporting properties and is initially well tolerated in vivo, the long-term
implications of, possibly irreversible, bone uptake would need to be carefully examined before
this complex could be considered as an MRI contrast agent for clinical applications.
Cationic LnDOTA-Tetraamide Complexes
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At low doses, all 3 cationic complexes studied here, Ln3, Ln5, and Ln6, were well tolerated
when administered intravenously by tail-vein injection. The biodistribution profiles show that
each of these complexes is primarily excreted through the renal system, and like the anionic
complexes, excretion is rapid. In vitro these cationic LnDOTA-tetra-amide complexes are as
kinetically inert to dissociation as their anionic counterparts,28,34 so it is likely that they are
sufficiently inert to avoid dissociation in vivo. However, although the biodistribution data
acquired for the 3 cationic complexes studied here do not suggest any gross dissociation of the
complexes, it is noteworthy that the level of activity recorded in organs associated with free
Ln3+ ion uptake (bone, liver, and spleen) is slightly higher for the cationic complexes than that
for the anionic complexes, the bone uptake of Gd1 being the notable exception. The increased
activity in the liver observed for 177Lu3 relative to that of 177Lu2 does not seem to be the result
of an increase in hydophobicity arising from the presence of a second ethyl group per
phosphonate. The 2 complexes have very similar and negative log P values: log P = −3.77 ±
0.37 (177Lu2) and log P = −3.37 ± 0.19 (177Lu3). Complexes with large negative log P values
usually require organic targeting groups, such as the aromatic substituents of GdEOB-DTPA
and GdBOPTA, to induce liver uptake through hepatocytes.44–46 Since such groups are absent
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from 177Lu3 and 177Lu4, they would not normally be expected to clear through the liver,
although the aromatic groups of 177Lu6 may induce some hepatobiliary clearance.44 – 46 There
are 2 possible explanations for the elevated activity levels observed in the spleen and liver for
tri-cationic complexes: the least likely is that a small quantity of complex dissociates in vivo
and that the Ln3+ ion is liberated. The absence of significant bone uptake at later time points
would allow complex dissociation to be definitively ruled out.35,36 However, it seems more
likely that the cationic complex remains intact, but as a result of its charge, it exhibits behavior
that parallels that of the free ion, forming colloids that are subsequently taken up by the liver
and spleen. This behavior is particularly evident in the case of Ln6, which is known to associate
with serum proteins.8 The idea that the tri-cationic DOTA-tetraamide complexes exhibit in
vivo behavior that parallels that of the free Ln3+ ion is supported by the observed toxicity of
these cationic complexes at higher doses.
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Complexes Ln5 and Ln6, when administered to rodents by tail vein injection at a typical MRI
dosage (0.1 mmol kg−1), were found to be acutely toxic. Death was rapid, within 1 minute of
injection, much too rapid to have been 1 caused by dissociation of the Ln3+ ion from the chelate
cage, which is known to be slow.34 The perfused heart study with Ln5 suggests clearly shows
that the complex itself has a negative impact on heart function and presumably a high enough
dose will stop heart function altogether. Although mono-cationic CT agents have been found
to be relatively toxic,47– 49 there are some differences in the observed behavior of these 2
classes of compound. The onset of death after administration of tri-cationic DOTA-tetraamide
complexes appears to be more rapid than after administration of mono-cationic CT agents.
Furthermore, the CT agents were observed to cause motor paresis and cessation of breathing
before death.48 Cardiac function was not impaired, leading to the suggestion that CT agents
had high neural toxicity.48 Tri-cationic DOTA-tetraamide complexes did not seem to cause
cessation of breathing before death, which seems to indicate that the origin of toxicity in these
2 cationic systems is quite different.
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A dose of 0.1 mmol kg−1 would afford an average blood concentration level in the region of
1.4 mM. From Figure 6, it can be seen that this amount of Ln5 in the KH perfusion buffer had
little negative impact on heart function. However, in this study, rats were administered a bolus
injection into the tail vein. The tail vein joins the inferior vena cava, which takes the bolus of
the complex directly to the right heart. From there the complex is pumped to the lungs and
back to the left heart. This means that immediately postinjection, the heart is exposed to a bolus
of the complex at very high concentration.50 This effect is clearly visible in the first γ-images
of a rat after administration of Ln6 (Fig. 4, top right). This exposure of heart tissue to high
concentrations of a tri-cationic complex in the immediate aftermath of a tail vein injection is
likely to compromise heart function to such an extent that the onset of death postinjection is
rapid. The nature of the interaction between heart tissue and Eu5 remains to be determined but
most likely involves the interference of the intact complex with the function of ion channels
of the myocytes.
Like cationic CT agents,47– 49 tri-cationic DOTA-tetra-amide complexes are clearly toxic
when used at higher doses. An alternative method of administration, perhaps via intraperitoneal injection or a slower infusion of the agent into the body, may be able to reduce the
acute toxicity observed with the cationic complexes Ln5 and Ln6. The toxicity of Ln3+ ions is
well known to be highly dependent upon the method of administration.35 However, the i.v.
toxicity observed in these experiments clearly precludes the use of these cationic DOTAtetraamide complexes in applications requiring the i.v. administration of higher effective doses,
such as MRI contrast agents. It has been previously reported that negatively charged
macrocyclic contrast agents are well tolerated by the cardiovascular system.51,52 Our
experiments with anionic DOTA-tetraamide complexes indicate that one way in which the
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problem of complex toxicity can be overcome is by the use of negatively charged ligand
systems such as 2 or 4.
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APPENDIX 1
Ligand 1 = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylenephosphonate;
2 = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene-(ethyl) phosphonate;
3 = 1,4, 7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene-(diethyl)
phosphonate; 4 = 1,4,7,10-tetraazacyclododecane-1,4, 7,10tetraacetamidomethylenecarboxylate; 5 = 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetamidomethylene-(ethyl)carboxylate; and 6 = 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene-2-(3-hydroxypyridine).

Invest Radiol. Author manuscript; available in PMC 2009 June 16.

Woods et al.

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

FIGURE 1.

The structure of some DOTA-tetraamide complexes. “Ln” is a generic symbol for a lanthanide
ion.
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FIGURE 2.

The CEST spectrum of a 50 mM solution of Eu2 recorded at 7 T, pH 7, 23°C, and B1 = 450
Hz, 320 Hz, 230 Hz, 160 Hz and 110 Hz, irr. time = 2 s. The solid lines are fits to the
experimental data.
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FIGURE 3.

The blood clearance of coinjected 153Gd1 (open diamond, dotted line) and 111InDTPA (filled
circles, dashed line) demonstrating the more rapid clearance kinetics of Gd1.
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FIGURE 4.

γ-Images of a rat administered with 153Sm6. Sixty-second images were taken at 1 minute (upper
left), 5 minutes (upper middle), and 9 minutes (upper right) postinjection. A composite γ-image
of all 9 frames from the sequential 60-second acquisitions (below).
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FIGURE 5.
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Averaged time-activity curves for the liver-spleen (light grey), thorax (black), kidney (dark
grey) obtained from the γ-images of 153Sm6. The curves were normalized relative to the
maximum activity obtained from dynamic acquisitions.
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FIGURE 6.

The effect of adding Eu5 to a perfused rat heart on the developed pressure of the heart.
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0.062 ± 0.036
0.026 ± 0.011
0.078 ± 0.048
0.033 ± 0.013
0.045 ± 0.029
0.051 ± 0.027
0.070 ± 0.060
0.152 ± 0.158
3.076 ± 2.466
0.082 ± 0.063
0.007 ± 0.004
0.580 ± 0.162
0.021 ± 0.015
0.028 ± 0.013

Blood

Heart

Lung

Liver

Spleen

Stomach

Sml. Int.

Lrg. Int.

Kidney

Pancreas

Brain

Bone

Muscle

Fat

Gd1n−

153

Lu2−

0.005 ± 0.001

0.007 ± 0.003

0.002 ± 0.001

0.003 ± 0.001

0.015 ± 0.006

0.398 ± 0.012

0.033 ± 0.036

0.016 ± 0.003

0.020 ± 0.006

0.030 ± 0.006

0.037 ± 0.008

0.019 ± 0.005

0.008 ± 0.003

0.005 ± 0.002

177

0.032 ± 0.015

0.018 ± 0.008

0.053 ± 0.019

0.006 ± 0.003

0.033 ± 0.023

0.909 ± 0.098

1.883 ± 1.670

0.041 ± 0.008

0.110 ± 0.049

0.048 ± 0.006

0.108 ± 0.023

0.085 ± 0.031

0.029 ± 0.026

0.040 ± 0.008

Lu33+

177

0.014 ± 0.004
0.009 ± 0.005

—

0.149 ± 0.063

0.004 ± 0.001

0.024 ± 0.006

0.614 ± 0.078

0.035 ± 0.013

0.027 ± 0.011

0.039 ± 0.009

0.039 ± 0.003

0.050 ± 0.009

0.026 ± 0.011

0.049 ± 0.007

0.039 ± 0.007

Lu53+

177

0.003 ± 0.001

0.018 ± 0.005

0.003 ± 0.001

0.011 ± 0.000

0.281 ± 0.050

0.016 ± 0.039

0.151 ± 0.013

0.014 ± 0.006

0.233 ± 0.183

0.043 ± 0.020

0.021 ± 0.002

0.007 ± 0.003

0.020 ± 0.005

Lu4−

177

Lu63+

—

0.013 ± 0.006

0.079 ± 0.026

0.001 ± 0.007

0.026 ± 0.023

0.927 ± 0.285

0.014 ± 0.008

0.228 ± 0.058

0.032 ± 0.002

1.353 ± 0.443

0.354 ± 0.088

0.135 ± 0.028

0.048 ± 0.010

0.071 ± 0.024

177
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TABLE 2

NIH-PA Author Manuscript

NIH-PA Author Manuscript
7.327 ± 5.678
0.066 ± 0.046

Kidney

Pancreas

0.651 ± 0.282

0.270 ± 0.258

Large. Int.

2.807 ± 1.862

0.092 ± 0.064

Small. Int.

Fat

0.089 ± 0.046

Stomach

Muscle

0.033 ± 0.023

Spleen

0.007 ± 0.005

0.367 ± 0.114

Liver

32.927 ± 8.448

0.114 ± 0.071

Lung

Bone

0.024 ± 0.010

Heart

Brain

1.430 ± 0.796

Blood

Gd1n−

153

0.121 ± 0.026

0.072 ± 0.030

0.036 ± 0.027

0.003 ± 0.001

0.003 ± 0.001

0.264 ± 0.007

0.171 ± 0.110

0.028 ± 0.010

0.026 ± 0.010

0.017 ± 0.003

0.248 ± 0.033

0.020 ± 0.004

0.005 ± 0.002

0.060 ± 0.026

177

Lu2−

0.774 ± 0.362

0.178 ± 0.191

0.998 ± 0.359

0.007 ± 0.003

0.007 ± 0.004

0.597 ± 0.046

11.710 ± 10.453

0.113 ± 0.037

0.138 ± 0.060

0.027 ± 0.003

0.687 ± 0.150

0.088 ± 0.034

0.019 ± 0.017

0.485 ± 0.091

Lu33+

177

0.194 ± 0.092

0.070 ± 0.066

2.747 ± 1.144

0.005 ± 0.002

0.017 ± 0.005

0.449 ± 0.071

0.261 ± 0.126

0.117 ± 0.069

0.045 ± 0.016

0.019 ± 0.003

0.304 ± 0.051

0.052 ± 0.004

0.016 ± 0.004

0.466 ± 0.062

Lu53+

177
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TABLE 3

Pharmacokinetic Parameters From the Fitting of the Data in Figure 3 to a Two-Compartment Model
153

Gd1

111

InDTPA

Ratio

NIH-PA Author Manuscript

αt1/2 (min)

3.37 (0.20)

3.99 (0.49)

0.85* (0.06)

βt1/2 (min)

41.7 (12.0)

56.0 (17.9)

0.75* (0.05)

Elimination t1/2 (min)

12.8 (2.7)

20.7 (5.68)

0.62* (0.05)

AUC0–∞ (min · kg/L)

196 (49)

240 (76)

0.82* (0.08)

Vol dist (mL/kg)

248 (21)

294 (12)

0.84* (0.04)

MRT (min)

49 (16)

71 (24)

0.70* (0.04)

Clearance (mL/min/kg)

5.4 (1.6)

4.5 (1.7)

1.20* (0.11)

αt1/2 = half-life for distribution phase; βt1/2 = half-life for elimination phase; Vol dist = volume of distribution; AUC0 –∞ = area under curve from time
zero to infinity; MRT = mean residence time in blood.
*

indicates P < 0.002 by paired Student t test.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Invest Radiol. Author manuscript; available in PMC 2009 June 16.

